NDA 020789 · Advanz Pharma
Zonegran
Zonisamide · Oral · Anti-epileptic Agent
NovelLast checked: Nov 20, 2026Latest source record: Apr 13, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Mar 27, 2000
Approved uses
1
Original approval plus efficacy supplements
Registered trials
79
22 Phase 3, 1 recruiting
FAERS reports
14,830
11,239 serious, 894 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 27, 2000 Original approval · Type 1 - New Molecular Entity NovelReviewOther Important Information from FDALabel
3 products under this application
- ZONEGRAN · ZONISAMIDE 100MG · CAPSULE, ORAL · Prescription · TE AB
- ZONEGRAN · ZONISAMIDE 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
- ZONEGRAN · ZONISAMIDE 25MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Zonisamide" as an intervention, any sponsor and status, largest first.
Eisai LimitedEisai
NCT00215592 · 1,000 participants · Start Oct 2005 · Primary completion Jul 2007
Drug: Zonegran · For: Epilepsy
Sites: Innsbruck, Austria; Dianalund, Denmark; Glostrup Municipality, Denmark · 33 sites in all
- Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With ObesityPivotal-lookingCompleted
Orexigen Therapeutics, IncIndustry
NCT00709371 · 729 participants · Start Jul 2008 · Primary completion Apr 2009
Drug: Zonisamide SR placebo/ bupropion SR placebo; Zonisamide SR placebo/ bupropion SR 360 mg/day and 4 more · For: Obesity
Sites: Fairhope, Alabama; La Jolla, California; Denver, Colorado · 20 sites in all
- Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated ObesityPivotal-lookingCompleted
Orexigen Therapeutics, IncIndustry
NCT00339014 · 611 participants · Start May 2006 · Primary completion Aug 2007
Drug: Zonisamide CR and Bupropion SR · For: Obesity
Sites: Fairhope, Alabama; Los Angeles, California; San Diego, California · 15 sites in all
- Zonisamide Versus Topiramate in MigrainePivotal-lookingCompleted
Kafrelsheikh UniversityAcademic, hospital or other
NCT06347497 · 600 participants · Start Apr 1, 2024 · Primary completion Apr 1, 2026
Drug: Zonisamide 50 MG; Topiramate 50 MG · For: Migraine
Sites: Kafr ash Shaykh, Egypt
- Zonisamide Versus Propranolol in MigrainePivotal-lookingStatus unknown
Kafrelsheikh UniversityAcademic, hospital or other
NCT06361446 · 600 participants (planned) · Start Mar 29, 2024 · Primary completion Mar 30, 2025
Drug: Zonisamide 50 MG; Propranolol · For: Migraine
Sites: Kafr ash Shaykh, Egypt
- A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial EpilepsyPivotal-lookingCompleted
Eisai Inc.Eisai
NCT00477295 · 583 participants · Start May 2007 · Primary completion Dec 2010
Drug: Zonisamide; Carbamazepine · For: Epilepsy
Sites: Camperdown, Australia; Clayton, Australia; Fitzroy, Australia · 79 sites in all
- A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset SeizuresPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01713946 · 366 participants · Start Apr 29, 2013 · Primary completion Oct 25, 2017
Drug: RAD001; Placebo and 2 more · For: Tuberous Sclerosis Complex-associated Refractory Seizures
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 104 sites in all
- Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial SeizuresPivotal-lookingCompleted
Eisai Inc.Eisai
NCT00848549 · 295 participants · Start Oct 2008 · Primary completion Jun 2011
Drug: Zonisamide; Carbamazepine · For: Epilepsy
Sites: Camperdown, Australia; Bedford Park, Australia; Clayton, Australia · 133 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,707
- seizure1,667
- off label use953
- fatigue731
- somnolence688
- convulsion622
- dizziness584
- nausea581
- headache569
- fall521
- drug interaction482
- condition aggravated465
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 166 |
| 2005 | 182 |
| 2006 | 245 |
| 2007 | 236 |
| 2008 | 268 |
| 2009 | 305 |
| 2010 | 329 |
| 2011 | 490 |
| 2012 | 518 |
| 2013 | 446 |
| 2014 | 547 |
| 2015 | 777 |
| 2016 | 937 |
| 2017 | 706 |
| 2018 | 891 |
| 2019 | 1,058 |
| 2020 | 929 |
| 2021 | 1,148 |
| 2022 | 1,093 |
| 2023 | 1,023 |
| 2024 | 969 |
| 2025 | 946 |
| 2026 | 621 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zonegran (Zonisamide)
2024 spending
$20.9M
Beneficiaries
675
4,783 claims
Per beneficiary
$30,939
$21.43 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $21,955,276 |
| 2021 | $22,320,130 |
| 2022 | $22,805,969 |
| 2023 | $23,044,503 |
| 2024 | $20,884,145 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Epilepsy.
Marson AG, Maguire M, Ramaratnam S · BMJ Clin Evid 2009 · Systematic Review
- Epilepsy (partial).
Maguire M, Marson AG, Ramaratnam S · BMJ Clin Evid 2011 · Systematic Review
- Epilepsy (partial).
Maguire M, Marson AG, Ramaratnam S · BMJ Clin Evid 2010 · Systematic Review
- Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis.
Stinton C, McKeith I, Taylor JP, et al. · Am J Psychiatry 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacotherapy for obesity.
Ioannides-Demos LL, Proietto J, McNeil JJ · Drugs 2005 · Meta-Analysis, Review
- The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Marson A, Burnside G, Appleton R, et al. · Lancet 2021 · Clinical Trial, Phase IV, Multicenter Study
Sponsor: Advanz Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.